GENE ONLINE|News &
Daiichi Sankyo Advances Care Standards with Groundbreaking Cancer Treatment
Daiichi Sankyo, a pioneering pharmaceutical company, is set to unveil new research in its DXd antibody drug conjugate (ADC) portfolio at the 2023 European Society for Medical Oncology (ESMO) Congress taking place in Madrid, Spain from October 20 to 24, 2023. The company’s presentation includes three late-breaking abstracts, with two of them featured in Presidential Symposia. These presentations offer a glimpse of Daiichi Sankyo’s commitment to redefining cancer treatment standards.
Related article: 2023 ASCO Annual Meeting: Progress in Solid Tumor Treatment Research, and Promising Results in Emerging Therapies
Daiichi Sankyo’s ESMO 2023 Presentation Highlights Progress
During ESMO 2023, Daiichi Sankyo will demonstrate its leadership in cancer care through more than 20 abstracts, featuring its innovative DXd antibody drug conjugate (ADC) portfolio. The focus of these abstracts is to showcase how the company is advancing treatment standards for various cancer types.
One of the most anticipated highlights at ESMO 2023 will be the results from the TROPION-Breast01 and TROPION-Lung01 phase 3 trials. These pivotal trials, presented in Presidential Symposium 3, will feature data on datopotamab deruxtecan (Dato-DXd). Dato-DXd’s effectiveness will be evaluated against chemotherapy in patients with hormone receptor-positive, HER2 low or negative metastatic breast cancer and advanced non-small cell lung cancer (NSCLC). The results of these trials promise to revolutionize the way certain patients with these conditions are treated, marking a significant step forward in cancer care.
Late-breaking data also includes the unveiling of progression-free and overall survival results from the DESTINY-PanTumor02 phase 2 trial. This trial evaluates ENHERTU® (trastuzumab deruxtecan) across multiple HER2-expressing solid tumors. These tumors include biliary tract, bladder, cervical, endometrial, ovarian, pancreatic, and other cancers. The presentation of these results will take cancer care to a new level by providing more effective and comprehensive treatments for these conditions.
Promising Results in Battling Multiple Types of Cancer
The exciting wave of research from Daiichi Sankyo doesn’t stop with Dato-DXd and ENHERTU. The company also has an array of other trials across its DXd ADC portfolio, promising advancements in different areas of cancer care.
One mini-oral session focuses on an exploratory analysis of the intracranial efficacy of patritumab deruxtecan (HER3-DXd) in patients with EGFR-mutated metastatic NSCLC. This research stems from the HERTHENA-Lung01 phase 2 trial, providing vital insights into improving care for patients with these specific conditions.
Additionally, a first-in-human phase 1 trial explores raludotatug deruxtecan (R-DXd) in patients with previously treated ovarian cancer, offering new hope to those with this challenging disease.
An exciting poster presentation will feature updated clinical and biomarker results of ifinatamab deruxtecan (I-DXd) in patients with advanced solid tumors. This is a result of an ongoing phase 1/2 trial that promises to expand the boundaries of cancer treatment.
Paving the Way for New Cancer Treatment Paradigms
Daiichi Sankyo’s research at ESMO 2023 promises to change the face of cancer treatment. With a robust portfolio of DXd ADCs, including ENHERTU, Dato-DXd, HER3-DXd, I-DXd, R-DXd, and DS-3939, the company aims to target and deliver a cytotoxic payload inside cancer cells that express specific cell surface antigens. The exciting presentations offer a glimpse of the potential to enhance cancer care and transform the current standards of treatment.
In conclusion, Daiichi Sankyo’s significant contributions to the field of cancer care at ESMO 2023 promise to usher in new and improved treatment paradigms, offering a glimmer of hope to patients battling various types of cancer.
Related posts:
